Skip to main content
Erschienen in: Neurocritical Care 2/2009

01.10.2009 | Original Article

Intra-Arterial Thrombolysis Within Three Hours of Stroke Onset in Middle Cerebral Artery Strokes

verfasst von: Eric C. Bourekas, Andrew Slivka, Rajul Shah, Yousef Mohammad, H. Wayne Slone, Dimitris T. Kehagias, Jose Suarez, Jeffrey Sunshine, Osama O. Zaidat, Robert Tarr, Dennis M. Landis, M. Fareed K. Suri, Adnan I. Qureshi

Erschienen in: Neurocritical Care | Ausgabe 2/2009

Einloggen, um Zugang zu erhalten

Abstract

Background and Purpose

The Prolyse in Acute Cerebral Thromboembolism II (PROACT II) trial showed improved outcomes in patients with proximal middle cerebral artery (MCA) occlusions treated with intra-arterial (IA) thrombolysis within 6 h of stroke onset. We analyzed outcomes of patients with proximal MCA occlusions treated within 3 h of stroke onset in order to determine the influence of time-to-treatment on clinical and angiographic outcomes in patients receiving IA thrombolysis.

Methods

Thirty-five patients from three academic institutions with angiographically demonstrated proximal MCA occlusions were treated with IA thrombolytics within 3 h of stroke onset. Outcome measures included outcomes at 30–90 day follow-up, recanalization rates, incidence of symptomatic intracranial hemorrhage, and mortality in the first 90 days. The endpoints were compared to the IA treated and control groups of the PROACT II trial.

Results

The median admission National Institutes of Health Stroke Scale (NIHSS) score was 16 (range 4–24). The mean time to initiation of treatment was 106 min (range 10–180 min). Sixty-six percent of patients treated, had a modified Rankin Scale (mRS) score of 2 or less at 1–3 month follow-up compared to 40% in the PROACT II trial. The recanalization rate was 77% (versus 66% in PROACT II). The symptomatic intracranial hemorrhage rate was 11% (versus 10% in PROACT II) and the mortality rate was 23% (versus 25% in PROACT II).

Conclusion

Time-to-treatment is just as important in IA thrombolysis as it is in IV thrombolysis, both for improving clinical outcomes and recanalization rates as well.
Literatur
1.
Zurück zum Zitat Sussman BJ, Fitch TSP. Thrombolysis with fibrinolysis in cerebral arterial occlusion. JAMA. 1958;167:1705–9. Sussman BJ, Fitch TSP. Thrombolysis with fibrinolysis in cerebral arterial occlusion. JAMA. 1958;167:1705–9.
2.
Zurück zum Zitat del Zoppo GJ, Higashida RT, Furlan AJ, Pessin MS, Rowley HA, Gent M, et al. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. Stroke. 1998;29(1):4–11.PubMed del Zoppo GJ, Higashida RT, Furlan AJ, Pessin MS, Rowley HA, Gent M, et al. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. Stroke. 1998;29(1):4–11.PubMed
3.
Zurück zum Zitat Furlan A, Higashida RT, Wechsler L, et al. for the PROACT Investigators: Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. JAMA. 1999;282(21):2003–11. doi:10.1001/jama.282.21.2003. Furlan A, Higashida RT, Wechsler L, et al. for the PROACT Investigators: Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. JAMA. 1999;282(21):2003–11. doi:10.​1001/​jama.​282.​21.​2003.
5.
Zurück zum Zitat Marler J, Tilley BC, Lu M, et al. Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study. Neurology. 2000;55(11):1649–55.PubMed Marler J, Tilley BC, Lu M, et al. Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study. Neurology. 2000;55(11):1649–55.PubMed
8.
Zurück zum Zitat del Zoppo G, Ferbert A, Otis S, et al. Local intra-arterial fibrinolytic therapy in acute carotid territory stroke. A pilot study. Stroke. 1988;19(3):307–13.PubMed del Zoppo G, Ferbert A, Otis S, et al. Local intra-arterial fibrinolytic therapy in acute carotid territory stroke. A pilot study. Stroke. 1988;19(3):307–13.PubMed
9.
Zurück zum Zitat Hacke W, Zeumer H, Ferbert A, Bruckman H, del Zoppo G. Intra-arterial thrombolytic therapy improves outcome in patients with acute vertebrobasilar occlusive disease. Stroke. 1988;19(10):1216–22.PubMed Hacke W, Zeumer H, Ferbert A, Bruckman H, del Zoppo G. Intra-arterial thrombolytic therapy improves outcome in patients with acute vertebrobasilar occlusive disease. Stroke. 1988;19(10):1216–22.PubMed
10.
Zurück zum Zitat Mori E, Tabuchi M, Yoshida T, Yamadori A. Intracarotid urokinase with thromboembolic occlusion of the middle cerebral artery. Stroke. 1988;9(7):802–12. Mori E, Tabuchi M, Yoshida T, Yamadori A. Intracarotid urokinase with thromboembolic occlusion of the middle cerebral artery. Stroke. 1988;9(7):802–12.
12.
Zurück zum Zitat Theron J, Courtheoux P, Casasco A, et al. Local intraarterial fibrinolysis in the carotid territory. AJNR Am J Neuroradiol. 1989;10(4):753–65.PubMed Theron J, Courtheoux P, Casasco A, et al. Local intraarterial fibrinolysis in the carotid territory. AJNR Am J Neuroradiol. 1989;10(4):753–65.PubMed
13.
Zurück zum Zitat Suarez JI, Sunshine JL, Tarr R, et al. Predictors of clinical improvement, angiographic recanalization, and intracranial hemorrhage after intra-arterial thrombolysis for acute ischemic stroke. Stroke. 1999;30(10):2094–100.PubMed Suarez JI, Sunshine JL, Tarr R, et al. Predictors of clinical improvement, angiographic recanalization, and intracranial hemorrhage after intra-arterial thrombolysis for acute ischemic stroke. Stroke. 1999;30(10):2094–100.PubMed
14.
Zurück zum Zitat Gonner F, Remonda L, Mattle H, et al. Local intra-arterial thrombolysis in acute stroke. Stroke. 1998;29:1894–900.PubMed Gonner F, Remonda L, Mattle H, et al. Local intra-arterial thrombolysis in acute stroke. Stroke. 1998;29:1894–900.PubMed
16.
Zurück zum Zitat Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. for the ATLANTIS Study Investigators. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS study: a randomized controlled trial. JAMA. 1999;82(21):2019–26. doi:10.1001/jama.282.21.2019. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. for the ATLANTIS Study Investigators. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS study: a randomized controlled trial. JAMA. 1999;82(21):2019–26. doi:10.​1001/​jama.​282.​21.​2019.
17.
Zurück zum Zitat Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with reconmbinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274:1017–25. doi:10.1001/jama.274.13.1017.PubMedCrossRef Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with reconmbinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274:1017–25. doi:10.​1001/​jama.​274.​13.​1017.PubMedCrossRef
18.
Zurück zum Zitat Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet. 1998;352:1245–51. doi:10.1016/S0140-6736(98)08020-9.PubMedCrossRef Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet. 1998;352:1245–51. doi:10.​1016/​S0140-6736(98)08020-9.PubMedCrossRef
19.
20.
Zurück zum Zitat Kanter D, Kothari R, Panioloi A, et al. The greater Cincinnati tPA experience after the NINDS trial: does a longer time to treatment within the current 3-hour window reduce efficacy? (Abstract). Presented at 24th Annual American Heart Association International Conference on Stroke and Cerebral Circulation, February 5, 1999; Nashville, TN. Kanter D, Kothari R, Panioloi A, et al. The greater Cincinnati tPA experience after the NINDS trial: does a longer time to treatment within the current 3-hour window reduce efficacy? (Abstract). Presented at 24th Annual American Heart Association International Conference on Stroke and Cerebral Circulation, February 5, 1999; Nashville, TN.
21.
Zurück zum Zitat Endo S, Kuwayama N, Hirashima Y, Takuya A, Nishijima M, Takaku A. Results of urgent thrombolysis in patients with major stroke and atherothrombotic occlusion of the cervical internal carotid artery. AJNR Am J Neuroradiol. 1998;19:1169–75.PubMed Endo S, Kuwayama N, Hirashima Y, Takuya A, Nishijima M, Takaku A. Results of urgent thrombolysis in patients with major stroke and atherothrombotic occlusion of the cervical internal carotid artery. AJNR Am J Neuroradiol. 1998;19:1169–75.PubMed
23.
Zurück zum Zitat Jahan R, Duckwiler GR, Kidwell CS, et al. Intraarterial thrombolysis for treatment of acute stroke: experience in 26 patients with long-term follow-up. AJNR Am J Neuroradiol. 1999;20:1291–9.PubMed Jahan R, Duckwiler GR, Kidwell CS, et al. Intraarterial thrombolysis for treatment of acute stroke: experience in 26 patients with long-term follow-up. AJNR Am J Neuroradiol. 1999;20:1291–9.PubMed
24.
Zurück zum Zitat Tomsick T, Brott T, Barsan W, et al. Prognostic value of the hyperdense middle cerebral artery sign and stroke scale score before ultraearly thrombolytic therapy. AJNR Am J Neuroradiol. 1996;17:79–85.PubMed Tomsick T, Brott T, Barsan W, et al. Prognostic value of the hyperdense middle cerebral artery sign and stroke scale score before ultraearly thrombolytic therapy. AJNR Am J Neuroradiol. 1996;17:79–85.PubMed
26.
Zurück zum Zitat Wolpert SM, Bruckmann H, Greenlee R, Wechsler L, Pessin, del Zoppo GJ, et al. Neuroradiologic evaluation of patients with acute stroke treated with recombinant tissue plasminogen activator. AJNR Am J Neuroradiol. 1993;14:3–13.PubMed Wolpert SM, Bruckmann H, Greenlee R, Wechsler L, Pessin, del Zoppo GJ, et al. Neuroradiologic evaluation of patients with acute stroke treated with recombinant tissue plasminogen activator. AJNR Am J Neuroradiol. 1993;14:3–13.PubMed
Metadaten
Titel
Intra-Arterial Thrombolysis Within Three Hours of Stroke Onset in Middle Cerebral Artery Strokes
verfasst von
Eric C. Bourekas
Andrew Slivka
Rajul Shah
Yousef Mohammad
H. Wayne Slone
Dimitris T. Kehagias
Jose Suarez
Jeffrey Sunshine
Osama O. Zaidat
Robert Tarr
Dennis M. Landis
M. Fareed K. Suri
Adnan I. Qureshi
Publikationsdatum
01.10.2009
Verlag
Humana Press Inc
Erschienen in
Neurocritical Care / Ausgabe 2/2009
Print ISSN: 1541-6933
Elektronische ISSN: 1556-0961
DOI
https://doi.org/10.1007/s12028-009-9198-8

Weitere Artikel der Ausgabe 2/2009

Neurocritical Care 2/2009 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.